B cells: more than just for antibodies in SARS-CoV-2 vaccine responses

Michael A. Paley; Alfred H.J. Kim

doi:10.1016/S2665-9913(21)00280-0

B cells: more than just for antibodies in SARS-CoV-2 vaccine responses

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	e741-e743
Journal	The Lancet Rheumatology
Volume	3
Issue number	11
DOIs	https://doi.org/10.1016/S2665-9913(21)00280-0
State	Published - Nov 2021

Access to Document

10.1016/S2665-9913(21)00280-0

Cite this

@article{943e1e0681b0461e8e92a89c87cfda05,

title = "B cells: more than just for antibodies in SARS-CoV-2 vaccine responses",

author = "Paley, {Michael A.} and Kim, {Alfred H.J.}",

note = "Funding Information: MAP has received funding from the Rheumatology Research Foundation, Arthritis National Research Foundation, and Civilian Research and Development Foundation Global. AHJK has received funding from the Rheumatology Research Foundation, National Institutes of Health, The Leona M and Harry B Helmsley Charitable Trust, GlaxoSmithKline, National Multiple Sclerosis Society, and Midwest Strategic Pharma-Academic Research Consortium, and consulting and speaking fees from Exagen Diagnostics, GlaxoSmithKline, Annexon, Aurinia Pharmaceuticals, and Alexion Pharmaceuticals.",

year = "2021",

month = nov,

doi = "10.1016/S2665-9913(21)00280-0",

language = "English",

volume = "3",

pages = "e741--e743",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

number = "11",

}

TY - JOUR

T1 - B cells

T2 - more than just for antibodies in SARS-CoV-2 vaccine responses

AU - Paley, Michael A.

AU - Kim, Alfred H.J.

N1 - Funding Information: MAP has received funding from the Rheumatology Research Foundation, Arthritis National Research Foundation, and Civilian Research and Development Foundation Global. AHJK has received funding from the Rheumatology Research Foundation, National Institutes of Health, The Leona M and Harry B Helmsley Charitable Trust, GlaxoSmithKline, National Multiple Sclerosis Society, and Midwest Strategic Pharma-Academic Research Consortium, and consulting and speaking fees from Exagen Diagnostics, GlaxoSmithKline, Annexon, Aurinia Pharmaceuticals, and Alexion Pharmaceuticals.

PY - 2021/11

Y1 - 2021/11

UR - http://www.scopus.com/inward/record.url?scp=85117883076&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(21)00280-0

DO - 10.1016/S2665-9913(21)00280-0

M3 - Comment/debate

C2 - 34514435

AN - SCOPUS:85117883076

SN - 2665-9913

VL - 3

SP - e741-e743

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 11

ER -

B cells: more than just for antibodies in SARS-CoV-2 vaccine responses

Access to Document

Other files and links

Cite this